Skip to Content

Olinvo Approval Status

FDA Approved: No
Brand name: Olinvo
Generic name: oliceridine
Dosage form: Injection
Company: Trevena, Inc.
Treatment for: Pain

Olinvo (oliceridine) is a G protein biased ligand of the mu opioid receptor, a new class of opioid receptor modulator in development for the treatment of moderate-to-severe acute pain.

Development Status and FDA Approval Process for Olinvo

DateArticle
Mar 11, 2019Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
Nov  2, 2018Trevena Receives Complete Response Letter for Oliceridine from FDA
Oct 11, 2018Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
Jan  2, 2018Trevena Announces FDA Acceptance for Review of New Drug Application for Olinvo (oliceridine) Injection
Nov  2, 2017Trevena Announces Submission of New Drug Application to U.S. FDA for Olinvo (oliceridine injection)
Jun 24, 2014Results of Phase 1b Clinical Trial Comparing Trevena’s TRV130 to Morphine Published in the Journal Pain

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide